Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Vertex Pharmaceuticals (NQ: VRTX ) 495.89 +2.54 (+0.51%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 30, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Vertex Pharmaceuticals < Previous 1 2 3 4 5 6 7 8 9 ... 51 52 Next > 3 High-Flying Stocks That Could Soar Even More May 25, 2024 The momentum should continue for Eli Lilly, Novo Nordisk, and Vertex Pharmaceuticals. Via The Motley Fool Spotlight on Vertex Pharmaceuticals: Analyzing the Surge in Options Activity May 23, 2024 Via Benzinga SLB, First Solar And 2 Other Stocks Insiders Are Selling May 23, 2024 Via Benzinga Walmart, Vertex Pharmaceuticals And More On CNBC's 'Final Trades' May 23, 2024 Walmart Inc. reported a "really strong" quarter, with e-commerce sales surging 21%. Adjusted EPS was 60 cents. Via Benzinga The 2030 Millionaire’s Club: 3 Biotech Stocks to Buy Now May 23, 2024 With interest cuts on the horizon, it's a prime time to consider these high-risk-high-reward biotech stocks to buy. Via InvestorPlace Vertex to Participate in Upcoming June Investor Conferences May 22, 2024 From Vertex Pharmaceuticals Incorporated Via Business Wire Should you consider NASDAQ:VRTX for quality investing? May 22, 2024 VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX) Exhibits Quality Stock Traits. Here's Why. Via Chartmill Vertex Pharmaceuticals's Options Frenzy: What You Need to Know May 15, 2024 Via Benzinga Halozyme Therapeutics Stock Earns IBD Stock Rating Upgrade, Hitting 80-Plus RS Rating May 16, 2024 On Thursday, biotech Halozyme Therapeutics stock had its Relative Strength (RS) Rating upgraded to 84, up from 80 a day earlier. Via Investor's Business Daily Is CRISPR Stock Going to $95? 1 Wall Street Analyst Thinks So. May 15, 2024 How much would you pay for a stock that might earn $25 a year in six years? Via The Motley Fool Jennifer Schneider Elected to Vertex Board of Directors May 15, 2024 From Vertex Pharmaceuticals Incorporated Via Business Wire Pfizer, Freeport-McMoRan, Vertex Pharmaceuticals And A Major Tech Stock On CNBC's 'Final Trades' May 15, 2024 Pfizer is looking to build on the success of its COVID-19 vaccine rollout by introducing a direct-to-consumer medicines platform. Via Benzinga Exposures COVID-19 A Closer Look at Vertex Pharmaceuticals's Options Market Dynamics May 08, 2024 Via Benzinga Catalyst Pharmaceuticals Stock Clears Technical Benchmark With 83 RS Rating May 14, 2024 On Tuesday, Catalyst Pharmaceuticals stock hit a key technical milestone, with its Relative Strength Rating climbing to 83 from 79. Via Investor's Business Daily 3 Cheap Biotech Stocks to Buy Now: May 2024 May 14, 2024 Many of these cheap biotech stocks are on their way to achieving FDA approval for their drugs to enter the market. Via InvestorPlace Exposures Product Safety Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 10 Years May 14, 2024 Via Benzinga Vertex Pharmaceuticals Is Racing Towards a New Blockbuster: Why the Stock Is a Smart Buy May 12, 2024 The biotech's shares dropped following its latest quarterly update, but that shouldn't matter to long-term investors. Via The Motley Fool 2 Unbelievable Growth Stocks You Can Buy and Hold for the Next Decade May 12, 2024 These companies are raking in profits at astonishing clips. Via The Motley Fool Stock Market Moves Toward Highs; Arista, Toast, Palantir Key Earnings Movers: Weekly Review May 10, 2024 Big earnings winners and losers continued. Via Investor's Business Daily Will the Biotech Sector Shift From Lagger to Leader? May 10, 2024 The biotech sector has experienced a significant rally after bouncing off uptrend support and is now consolidating near major SMAs. Via MarketBeat Topics ETFs Investors seeking growth at a reasonable cost should explore NASDAQ:VRTX. May 08, 2024 While growth is established for NASDAQ:VRTX, the stock's valuation remains reasonable. Via Chartmill 5 Reasons Vertex Pharmaceuticals Is a Screaming Buy on the Dip May 08, 2024 New drugs in development and a lack of significant patent cliffs ahead make this a great pharma stock to buy now and hold over the long run. Via The Motley Fool Topics Intellectual Property Exposures Intellectual Property Markets In A Minute - "A Lack Of Further Progress" May 07, 2024 May's FOMC meeting left the Fed Funds Rate unchanged. JOLTS showed fewer job openings with increased layoffs. April's job report disappointed, adding only 175k jobs and seeing higher unemployment.... Via Talk Markets Topics Economy Workforce Exposures Interest Rates Layoff 10 Health Care Stocks With Whale Alerts In Today's Session May 07, 2024 Via Benzinga US Stocks Eye Fourth Positive Session Despite Hawkish Fed Remarks; Disney, Palantir Tumble; Treasury Yields Fall: What's Driving Markets Tuesday? May 07, 2024 Wall Street experienced a quiet session during morning trading on Tuesday, influenced by a lack of significant economic data and minimal updates on earnings from major large-cap companies. Via Benzinga Topics Economy Exposures Interest Rates VRTX Stock Earnings: Vertex Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 May 06, 2024 VRTX stock results show that Vertex Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. Via InvestorPlace Vertex Pharmaceuticals (VRTX) Q1 2024 Earnings Call Transcript May 06, 2024 VRTX earnings call for the period ending March 31, 2024. Via The Motley Fool Topics Earnings Exposures Financial Vertex Beats First-Quarter Expectations, But Shares Stay Flat On Reiterated Outlook May 06, 2024 Vertex Pharmaceuticals beat first-quarter sales and earnings forecasts. Via Investor's Business Daily Vertex Reports First Quarter 2024 Financial Results May 06, 2024 From Vertex Pharmaceuticals Incorporated Via Business Wire 3 Biotech Stocks to Double Your Money in the Next 24 Months May 06, 2024 The biotech sector offers significant potential for growth. These 3 biotech stocks to double your money are noteworthy candidates. Via InvestorPlace < Previous 1 2 3 4 5 6 7 8 9 ... 51 52 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.